

TriLink BioTechnologies and International Vaccine Institute ink MoU to support development of mRNA-based vaccines

15 May 2025 | News

To promote equitable access to essential vaccines and health technologies



US-based TriLink BioTechnologies, a Maravai LifeSciences company and global provider of life science reagents and services, and South Korea-based International Vaccine Institute (IVI), a non-profit international organisation devoted to and the discovery, development and delivery of vaccines for global health, have signed a Memorandum of Understanding (MoU) to collaborate to advance the research and development of mRNA-based vaccines and promote equitable access to essential vaccines and health technologies.

According to the terms of the MoU, TriLink and IVI will enter discussions on collaborative models to develop vaccines using mRNA technologies, facilitate knowledge exchange, and support joint scientific initiatives.

Since its launch in 2017, TriLink's CleanCap capping technology has continued to advance the mRNA capping industry and is used in the majority of all approved COVID-19 mRNA and saRNA vaccines. In 2024, TriLink expanded its products and services specifically for customers working in mRNA therapeutics, launching IVT enzymes, including CleanScribe RNA polymerase, which has been shown to reduce dsRNA, and opened its commercially ready GMP manufacturing facility in San Diego, California.

"This collaboration will not only advance the science of mRNA-based vaccines but may also significantly enhance access to life-saving vaccines in low- and middle-income countries (LMICs)," said Maravai and TriLink's Chief Commercial Officer, Becky Buzzeo.

Image caption- Dr Jerome Kim, Director General of IVI (left), standing next to TriLink's Chief Commercial Officer, Becky Buzzeo